The order, entered July 15 by Judge Myong J. Joun in Amazentis SA et al. v. The Partnerships and Unincorporated Associations Identified on Schedule “A” permanently enjoins 19 defaulting defendants from manufacturing, marketing, distributing or selling Urolithin A products.
The court also ordered the defendants to pay Timeline damages ranging from $500 to more than $2.7 million each, based on the scale of their sales of fraudulent products. For several defendants, the court tripled the awards as enhanced damages, bringing the total award to more than $5.3 million. Timeline previously entered into stipulated judgments with those defendants that did appear in the case.
Case history and laboratory testing
Timeline and its U.S. subsidiary Timeline Longevity, Inc. initially filed suit in October 2025, alleging that 30 defendants operating through a network of online storefronts and private drop-ship stores sold products that either contained no detectable urolithin A or contained significantly less than the amount claimed on label.
The lawsuit followed independent laboratory testing commissioned by Timeline in 2023, which supported those allegations.
“Starting in 2023, copycat supplements purporting to contain Urolithin A began to appear on Amazon’s e-commerce platform sourced from one or more manufacturers,” the complaint read, noting that these products are sold much lower prices than Timeline’s proprietary Mitopure-branded Urolithin A.
“On information and belief, these fake and falsely labeled Urolithin A supplements appeared to have been manufactured by the same companies in the People’s Republic of China; this appears to be true based on the size, color and shape of the packaging and capsules [...],as well as based on other information contained on the Amazon storefronts for each product.”
The complaint further alleged that some defendants used the Mitopure trademark without authorization to promote the mislabeled products and made additional false and misleading claims, including that their products were made in the USA, were third-party tested and certified, and were vegan.
It also presented evidence that many defendants provided false address information on product packaging and listings and included undisclosed filler ingredients in their mislabeled Urolithin A products.
Although Timeline stated that it worked with Amazon to identify and remove “improper listings” from the platform, it noted in the complaint that “these and other fake urolithin A supplement sellers have since engaged in conduct to thwart those efforts” by selling under new and different brands, generating new product pages, selling under different seller names or moving to other e-commerce platforms.
Protecting the integrity of the market
The case is part of Timeline’s ongoing global enforcement program to protect consumers from counterfeit and mislabeled Urolithin A products and defend the clinical research and intellectual property behind Mitopure.
“We are very pleased with the court’s order that protects consumers and innovators like Timeline from bad actors who sell fraudulent products and misappropriate intellectual property,” Chris Rinsch, PhD, co-founder and president of Timeline, shared in a statement.
He highlighted that the company has invested over 18 years and more than $50 million to build the clinical evidence for Mitopure and will continue to “vigilantly protect the integrity of the market.”
“We will not hesitate to pursue available legal remedies against those who put consumers at risk and exploit our intellectual property without authorization,” he said.
